Sökning: WFRF:(Moens Lotte. N.) > Drug sensitivity te...
Fältnamn | Indikatorer | Metadata |
---|---|---|
000 | 05004naa a2200553 4500 | |
001 | oai:DiVA.org:uu-378986 | |
003 | SwePub | |
008 | 190319s2019 | |||||||||||000 ||eng| | |
009 | oai:prod.swepub.kib.ki.se:140324082 | |
024 | 7 | a https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-3789862 URI |
024 | 7 | a https://doi.org/10.1038/s41416-018-0359-42 DOI |
024 | 7 | a http://kipublications.ki.se/Default.aspx?queryparsed=id:1403240822 URI |
040 | a (SwePub)uud (SwePub)ki | |
041 | a engb eng | |
042 | 9 SwePub | |
072 | 7 | a ref2 swepub-contenttype |
072 | 7 | a art2 swepub-publicationtype |
100 | 1 | a Brodin, Bertha A.u Karolinska Institutet4 aut |
245 | 1 0 | a Drug sensitivity testing on patient-derived sarcoma cells predicts patient response to treatment and identifies c-Sarc inhibitors as active drugs for translocation sarcomas |
264 | c 2019-02-12 | |
264 | 1 | b Springer Science and Business Media LLC,c 2019 |
338 | a print2 rdacarrier | |
520 | a BACKGROUND: Heterogeneity and low incidence comprise the biggest challenge in sarcoma diagnosis and treatment. Chemotherapy, although efficient for some sarcoma subtypes, generally results in poor clinical responses and is mostly recommended for advanced disease. Specific genomic aberrations have been identified in some sarcoma subtypes but few of them can be targeted with approved drugs. METHODS: We cultured and characterised patient-derived sarcoma cells and evaluated their sensitivity to 525 anti-cancer agents including both approved and non-approved drugs. In total, 14 sarcomas and 5 healthy mesenchymal primary cell cultures were studied. The sarcoma biopsies and derived cells were characterised by gene panel sequencing, cancer driver gene expression and by detecting specific fusion oncoproteins in situ in sarcomas with translocations. RESULTS: Soft tissue sarcoma cultures were established from patient biopsies with a success rate of 58%. The genomic profile and drug sensitivity testing on these samples helped to identify targeted inhibitors active on sarcomas. The cSrc inhibitor Dasatinib was identified as an active drug in sarcomas carrying chromosomal translocations. The drug sensitivity of the patient sarcoma cells ex vivo correlated with the response to the former treatment of the patient. CONCLUSIONS: Our results show that patient-derived sarcoma cells cultured in vitro are relevant and practical models for genotypic and phenotypic screens aiming to identify efficient drugs to treat sarcoma patients with poor treatment options. | |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Cancer och onkologi0 (SwePub)302032 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Cancer and Oncology0 (SwePub)302032 hsv//eng |
700 | 1 | a Wennerberg, Kristeru Univ Helsinki, Inst Mol Med Finland FIMM, Helsinki, Finland; Univ Copenhagen, BRIC, Copenhagen, Denmark4 aut |
700 | 1 | a Lidbrink, Elisabetu Karolinska Univ Hosp, Dept Breast Canc Endocrine Tumors & Sarcoma, Stockholm, Sweden4 aut |
700 | 1 | a Brosjö, Otteu Karolinska Institutet4 aut |
700 | 1 | a Potdar, Swapnilu Univ Helsinki, Inst Mol Med Finland FIMM, Helsinki, Finland4 aut |
700 | 1 | a Wilson, Jennifer N.u Karolinska Inst, Dept Microbiol Tumor & Cell Biol MTC, Stockholm, Sweden4 aut |
700 | 1 | a Ma, Liminu Karolinska Inst, Dept Microbiol Tumor & Cell Biol MTC, Stockholm, Sweden4 aut |
700 | 1 | a Moens, Lotteu Uppsala universitet,Klinisk och experimentell patologi4 aut0 (Swepub:uu)lotmo617 |
700 | 1 | a Hesla, Asleu Karolinska Institutet4 aut |
700 | 1 | a Porovic, Edvinu Karolinska Inst, Dept Microbiol Tumor & Cell Biol MTC, Stockholm, Sweden4 aut |
700 | 1 | a Bernhardsson, Edvinu Karolinska Inst, Dept Microbiol Tumor & Cell Biol MTC, Stockholm, Sweden4 aut |
700 | 1 | a Papakonstantinou, Antroulau Karolinska Institutet4 aut |
700 | 1 | a Bauer, Henriku Karolinska Institutet4 aut |
700 | 1 | a Tsagkozis, Panagiotisu Karolinska Institutet4 aut |
700 | 1 | a von Sivers, Karinu Karolinska Univ Hosp, Dept Radiol, Stockholm, Sweden4 aut |
700 | 1 | a Wejde, Johanu Karolinska Univ Hosp, Dept Cytol & Pathol, Stockholm, Sweden4 aut |
700 | 1 | a Ostling, Paiviu Karolinska Institutet4 aut |
700 | 1 | a Kallioniemi, Olliu Karolinska Institutet4 aut |
700 | 1 | a Stragliotto, Christina Linderu Karolinska Univ Hosp, Dept Breast Canc Endocrine Tumors & Sarcoma, Stockholm, Sweden4 aut |
710 | 2 | a Karolinska Institutetb Univ Helsinki, Inst Mol Med Finland FIMM, Helsinki, Finland; Univ Copenhagen, BRIC, Copenhagen, Denmark4 org |
773 | 0 | t British Journal of Cancerd : Springer Science and Business Media LLCg 120:4, s. 435-443q 120:4<435-443x 0007-0920x 1532-1827 |
856 | 4 | u https://www.nature.com/articles/s41416-018-0359-4.pdf |
856 | 4 8 | u https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-378986 |
856 | 4 8 | u https://doi.org/10.1038/s41416-018-0359-4 |
856 | 4 8 | u http://kipublications.ki.se/Default.aspx?queryparsed=id:140324082 |
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
Kopiera och spara länken för att återkomma till aktuell vy